Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer
August 20 2024 - 8:30AM
Business Wire
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global
leader in life science research and clinical diagnostics products,
today announced that Jon DiVincenzo will join the company as
President and Chief Operating Officer, effective September 9, 2024,
replacing Andy Last, who is retiring.
Mr. DiVincenzo joins Bio-Rad from Labcorp Holdings Inc., a
global provider of comprehensive laboratory services, where he held
various global operational and commercial leadership roles across
the company’s several business units. Most recently, he served as
Executive Vice President and President, Central Laboratories and
International. Prior to LabCorp, Mr. DiVincenzo was President of
the Environmental Health Division at PerkinElmer, a global company
focused on diagnostics, life science research, food quality,
environmental health and industrial testing. He also served as
Chief Executive Officer of Enzymatics, a privately held molecular
biology reagents company. Prior to that, Mr. DiVincenzo held roles
of increasing responsibility in the Biosciences and Lab Water
businesses of EMD Millipore, a subsidiary of Merck KGaA. He holds a
Bachelor of Science degree in mechanical engineering from
Northeastern University.
"We are thrilled to welcome Jon DiVincenzo as our President and
Chief Operating Officer,” stated Norman Schwartz, Bio-Rad’s
Chairman and Chief Executive Officer. “Jon brings to Bio-Rad over
thirty years of industry experience across strategic, operational,
and commercial organizations in both life science and clinical
diagnostics. His extensive track record spans leadership roles in
operations, marketing, and product development, which will be
integral to our continued success.”
Mr. DiVincenzo stated, "I am excited to join Bio-Rad and I look
forward to working with the executive team to continue to make
progress towards achieving the company’s long-term transformational
and growth objectives.”
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in
developing, manufacturing, and marketing a broad range of products
for the life science research and clinical diagnostics markets.
Based in Hercules, California, Bio-Rad operates a global network of
research, development, manufacturing, and sales operations with
over 7,700 employees, and $2.7 billion in revenues in 2023. Our
customers include universities, research institutions, hospitals,
food safety and environmental quality laboratories, and
biopharmaceutical companies. Together, we develop innovative,
high-quality products that advance science and save lives. To learn
more, visit bio-rad.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240820682671/en/
Investor Contact: Edward Chung, Investor Relations
510-741-6104 ir@bio-rad.com
Media Contact: Anna Gralinska, Corporate Communications
510-741-6643 cc@bio-rad.com
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Oct 2024 to Nov 2024
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Nov 2023 to Nov 2024